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Background: Integration of double stranded viral DNA is a key step in the retroviral life cycle. Virally encoded
enzyme, integrase, plays a central role in this reaction. Mature forms of integrase of several retroviruses (i.e. HIV-1
and MLV) bear conserved destabilizing N-terminal residues of the N-end rule pathway - a ubiquitin dependent
proteolytic system in which the N-terminal residue of a protein determines its half life. Substrates of the N-end rule
pathway are recognized by E3 ubiquitin ligases called N-recognins. We have previously shown that the inactivation
of three of these N-recognins, namely UBR1, UBR2 and UBR4 in mouse embryonic fibroblasts (MEFs) leads to
increased stability of ectopically expressed HIV-1 integrase. These findings have prompted us to investigate the
involvement of the N-end rule pathway in the HIV-1 life cycle.
Results: The infectivity of HIV-1 but not MLV was decreased in N-recognin deficient cells in which three N-recognins
(UBR1, UBR2 and UBR4) were depleted. HIV-1 integrase mutants of N-terminal amino acids (coding for stabilizing or
destabilizing residues) were severely impaired in their infectivity in both human and mouse cells. Quantitative PCR
analysis revealed that this inhibition was mainly caused by a defect in reverse transcription. The decreased infectivity was
independent of the N-end rule since cells deficient in N-recognins were equally refractory to infection by the integrase
mutants. MLV integrase mutants showed no difference in their infectivity or intravirion processing of integrase.
Conclusions: The N-end rule pathway impacts the early phase of the HIV-1 life cycle; however this effect is not the result
of the direct action of the N-end rule pathway on the viral integrase. The N-terminal amino acid residue of integrase is
highly conserved and cannot be altered without causing a substantial decrease in viral infectivity.
Keywords: N-end rule, HIV-1, MLV, IntegraseBackground
Retroviruses are obligate intracellular parasites that must
exploit host cell pathways during their life cycle. These
activities range from using motor proteins [1], nuclear
import [2] and export pathways, to transcription [3] and
processing [4] of the viral genome. Studying the role of
these cellular pathways in retroviral replication can lead
to a deeper understanding of the viral life cycle. This has
been highlighted recently with the development of high
throughput screening techniques which have implicated
numerous proteins that are either required or act to
restrict retroviral infection [5-8]. One of the processes
repeatedly implicated in several genome wide screens
is the ubiquitin proteasome pathway that mediates signal* Correspondence: somia001@umn.edu
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reproduction in any medium, provided the ordependent degradation of proteins. Different proteins of
this pathway have been found in all four genome wide
RNAi screens conducted looking for host factors used by
HIV-1 [5-8]. Although over the years, a variety of studies
have implicated the ubiquitin proteasome system in the
viral life cycle, research on the role of this essential
pathway in retroviral infection has mostly been focused
on targeting of cellular restriction factors to the prote-
asome by viral accessory proteins [9-11]. Results of the
genomewide studies on host factors suggest that retrovi-
ruses may be using the ubiquitin proteasome pathway in
the early phase of the viral life cycle.
One of the degradation signals that target cellular pro-
teins to the proteasome is the N-terminal amino acid
residue of the protein. First described by Alex Varshavsky
and colleagues in 1986, this N-end rule is an ubiquitin
dependent proteolytic system in which the identity of the
N-terminal amino acid residue of a protein determines itsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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covered while expressing a bacterial protein in yeast cells
the N-end rule pathway was subsequently found to be
present in all organisms examined including mammals
[13], plants [14], and bacteria [15]. Hence it is an evolu-
tionarily ancient mechanism for protein degradation. In
mammalian cells, amino acids are classified as stabilizing
(Met, Ala, Val, Gly, Pro, Ser, Thr) or destabilizing (Glu,
Gln, Cys, Asp, Asn, Arg, Lys, His, Leu, Ile, Phe, Trp, Tyr)
based on their ability to act as a degradation signal for the
N-end rule pathway. Although the N-end rule classifies
most amino acids as destabilizing for the mammalian cells,
it has been difficult to identify the cellular substrates of this
pathway. However with the discovery of several signaling
components of the N-end rule pathway our understanding
of this process has increased in the last decade.
Specificity of the ubiquitin proteasome system is governed
by E3 ubiquitin ligases that recognize a degradation signal
on the target protein and catalyze the addition of ubiquitin
onto the protein. For the N-end rule pathway, these ligases
are called N-recognins, and the signal for degradation is
termed an N-degron [16]. The first N-recognin was discov-
ered in S. cerevisiae and termed Ubr1 [16]. While Ubr1 is
the sole N-recognin in yeast cells, subsequent studies have
identified two homologs of Ubr1 in mammalian genomes,
UBR1 and UBR2 [17]. These proteins have been shown
to have highly similar sequences and overlapping func-
tions [17,18]. Biochemical studies identified two more
E3 ligases that can bind to destabilizing N-terminal resi-
dues, termed UBR4 and UBR5 [18]. These proteins con-
tain a common zinc finger like domain termed a UBR box
[18]. Mammalian genomes contain three additional genes
that code for the UBR box domain, UBR3, UBR6 and
UBR7 [18]. However these proteins have not been shown
to bind any of the destabilizing residues and therefore
their role in the N-end rule pathway, if any, is unknown.
While recent studies on N-recognins have substantially
increased our understanding of the N-end rule pathway,
identification of the cellular substrates of N-end rule has
been challenging. Since almost all mammalian proteins
are synthesized with an N-terminal methionine, a stabiliz-
ing residue, an N-degron can only be created through post
translational modifications, such as the removal of the
N-terminal methionine [19] or endoproteolytic cleavage.
Proteolytic cleavage of certain viral proteins can generate
potential substrates for the N-end rule pathway. One viral
protein that has been studied with respect to the N-end
rule is the integrase of HIV-1. Retroviral integrase is
synthesized as a part of a Gag Pol polyprotein (Pol in
spumaretroviruses). Along with other viral proteins, Gag
Pol is packaged into viral particle during assembly and,
upon viral budding, the mature form of integrase is gener-
ated as a result of a series of proteolytic cleavage events
mediated by the viral protease. We have previously shownthat concomitant impairment of three of the N-recognins
that bind to destabilizing residues, UBR1, UBR2 and
UBR4 in mouse embryonic fibroblasts (MEFs) leads to
increased stability of ectopically expressed HIV-1 integrase
bearing a destabilizing residue [18]. These results and others
[20,21] raised the possibility that HIV-1 (and possibly other
retroviruses) may utilize the N-end rule pathway to control
the stability of integrase during viral infection.
In this study we investigated the potential role of the
N-end rule pathway during the early phase of the life
cycle of two different retroviruses; HIV-1 and MLV. Here
we show that HIV-1 but not MLV infectivity is decreased
in cells where the N-end rule pathway was impaired. We
also show that the N-terminal amino acid residue of HIV-1
integrase which has previously been suggested to be a tar-
get for degradation by the N-end rule is not targeted by the
N-end rule pathway during infection.
Results
Proteolytic cleavage of Gag/Pol generates destabilizing
N-end rule residues
We first examined whether the cleavage of the Gag Pol
polyprotein by HIV-1 protease would generate mature
proteins that expose destabilizing N-terminal residues of
the N-end rule pathway. Each HIV-1 protease cleavage
recognition site in the polyprotein between the subunits
differs in its amino acid sequence. Hence the nature of
the sequence and its accessibility is thought to determine
the specificity for cleavage [22]. Furthermore variation
among groups or subtypes of HIV may result in sequence
variation of the cleavage site. Therefore, we reasoned
that if HIV-1 utilizes the N-end rule in its lifecycle, the
N-terminal amino acids of mature protein should be
conserved as N-degrons across different types, groups
and subgroups of HIV-1. The conservation of N-terminal
destabilizing residues across other lentiviruses would also
suggest a selection pressure to maintain their interaction
with N-end rule machinery. A previous study has com-
pared HIV-1 type 1 protease cleavage sites and identified
the most common recent common ancestor (MRCA) of
protease cleavage sites in HIV-1 for groups M, B and C
[23]. Of note, 7 proteins are expected to bear N-terminal
destabilizing residues. We have further analyzed the con-
servation of the N-terminal residues of these 7 proteins by
comparing the sequences of 1850 HIV-1 isolates from the
Los Alamos HIV Sequence Database (http://www.hiv.lanl.
gov/). Of the sequences analyzed we have found that 4
proteins (p1, Trans frame octapeptide (TFP), RNaseH and
Integrase) have N-terminal amino acid sequences that are
conserved relative to the MRCA. The data is summarized
in Table 1 with respect to the N-terminal amino acid gen-
erated and its predicted behavior according to the N-end
rule. Result for the cleavage site between Reverse Tran-
scriptase and Integrase is shown in Figure 1. In this study
Table 1 HIV-1 proteins have N-terminal destabilizing residues
HIV-1 cleavage site and conservation Amino acid at the N terminus N-end rule designation
MA/CA Conserved Proline Stabilizing
CA/p2 Conserved Alanine Stabilizing
P2/NC Variable Methionine Stabilizing
NC/p1 Conserved Phenylalanine Primary Destabilizing
p1/p6(gag) Variable Leucine Primary Destabilizing
NC/TFP Conserved Phenylalanine Primary Destabilizing
TFP/p6(pol) Variable Leucine Primary Destabilizing
p6(pol)/PR Variable Proline Stabilizing
PR/RT Conserved Proline Stabilizing
RT/RH(p15) Conserved Tyrosine Primary Destabilizing
RH(p15)/INT Conserved Phenylalanine Primary Destabilizing
Nef Variable Leucine Primary Destabilizing
Comparison of 84 protease cleavage site sequences (27 C-type, 30 B-type and 27 M-type) [23]. The position and the conservation relatives to the most common
recent common ancestor (MRCA) are shown. The proteins that are conserved for a destabilizing residue as confirmed by an analysis of 1850 isolates of HIV-1 and
SIVcpz present in Los Alamos HIV Database (http://www.hiv.lanl.gov) are highlighted in bold.
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was implicated as a target for the N-end rule [18,20,21]
and since it is the focus of small molecule development to
combat HIV-1.
The N-end rule can impact HIV-1 infection
We next tested if the N-end rule can impact HIV-1 infec-
tion. To this end we utilized single cycle HIV-1 reporter
vectors and cell lines mutant in N-recognins. We have
previously characterized redundant functions of the UBR
proteins and hence generated cell lines singly or multiply
mutant for UBR proteins [18]. These are MEFs from
UBR1−/−, UBR2−/− and UBR1−/− UBR2−/− strains of
mice. We have also previously generated MEF lines that
are deficient in all three UBR box proteins (UBR1, UBR2R   K   V   L 
Figure 1 N terminal residue of HIV integrase is highly conserved. Ana
integrase of 1850 isolates of HIV-1 and SIVcpz present in Los Alamos HIV D
Corresponding amino acid for the conserved sequence is shown at the bo
(http://weblogo.berkeley.edu/). Arrows indicate the protease cleavage site.and UBR4) that have been shown to bind type 2 destabil-
izing residues by transducing UBR1−/− UBR2−/− cell
lines with 3 different shRNAs against UBR4 mRNA (to ac-
count for any off target effects) and a shRNA targeting lu-
ciferase mRNA as a control. UBR4 knockdown was
verified by immunoblotting [18]. Wild-type MEFs trans-
duced with shRNA to UBR4 mRNA were used to inves-
tigate the effect of UBR4 knockdown alone.
We infected N-recognin deficient MEFs with a HIV-1
EGFP vector pseudotyped with VSVG. Infectivity was
reported as EGFP expression and was scored by flow cy-
tometry 72hrs after infection. Figure 2 illustrates that the
infectivity of HIV-1 was unchanged over a range of MOIs
(Multiplicity of Infection) comparing wild type (WT),
MEFs for UBR1 −/−, UBR2 −/−, UBR4 KD, and the  F   L   D
lysis of sequence of the protease cleavage site between RT and
atabase (http://www.hiv.lanl.gov) using the web alignment tool.
ttom. The sequence logo at the top was generated using WebLogo
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Figure 2 HIV-1 infectivity is decreased when all three N-recognins are depleted. WT and N-recognin deficient MEFs were infected with
VSVG pseudotyped HIV-1-EGFP at an increasing MOI of 0.1, 0.5 and 1. The percent of GFP positive cells were determined by fluorescence
cytometry 3 days post infection.
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a substantial decrease (5–6 fold) only in cells that are
depleted in UBR1, UBR2 and UBR4. We confirmed that
this decrease in infectivity is not due to a defect in the
reporter or the expression of the reporter by using a dif-
ferent reporter (DS-Red) and a different promoter (CMV)
(Additional file 1: Figure S1).
HIV-1 infection is impaired at reverse transcription or
uncoating in N-recognin deficient cells
These results indicate that N-end rule pathway can im-
pact the early phase of the HIV-1 life cycle. However
decrease in infectivity by itself is not enough to deter-
mine whether the N-end rule acts on HIV-1 proteins or
a cellular protein that is involved in infection. To better
pinpoint the stage that is impaired we determined which
step in the viral life cycle is affected in the N-recognin de-
ficient MEFs. Following infection we isolated total DNA
from MEFs at different time points and tracked the rela-
tive accumulation of early reverse transcription products
and 2LTR circles by qPCR. As shown in Figure 2 the in-
fection in WT cells compared to UBR1−/− UBR2−/− cells
are similar. Therefore we chose to compare UBR1−/−
UBR2−/− Luci RNAi to UBR1−/− UBR2−/− UBR4 RNAi
cells. As shown in Figure 3A, UBR1−/− UBR2−/− UBR4
RNAi cells showed around 3–4 fold decrease in the accu-
mulation of first jump products. Moreover the rate ofincrease in the accumulation of first jump products
were found to be lower in the triply deficient cells espe-
cially in the early time points (compare 4 hour and 6
hour time points) indicating a defect in reverse tran-
scription. However the first point we analyzed also
showed around 2 fold difference in the amount of first
jump products between the control and the triply
deficient cells, which suggests that another defect be-
fore the first jump step of the reverse transcription
either at the start of reverse transcription or during
uncoating could contribute to this phenomenon. The
difference we observed in the accumulation of reverse
transcription products was further enhanced when we
looked at the relative production of 2LTR circles. As illus-
trated in Figure 3B, the UBR1−/− UBR2−/− UBR4RNAi
cells exhibited up to 7 fold less 2LTR circles compared to
the control cells. However, since the 2LTR circles are only
a subset of the reverse transcription products that enter
the nucleus we do not observe any defect in nuclear im-
port. Furthermore it has been reported that in the pres-
ence of mutant non-functional integrase 2LTR circles are
increased when compared to infection with wild type
integrase [24,25]. Hence we compared the ratio of first
jump to 2LTR circles at 24 hrs. The data show that for
UBR1−/− UBR2−/− LuciRNAi control cells the ratio is
216.7 ± 34.6, while the ratio in triply mutant cells is 250.3
± 53.9. This indicates that the integrase function is not
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Figure 3 Kinetics and nuclear localization of proviral DNA in N-recognin deficient cells. UBR1−/− UBR2−/− Luci RNAi (control) and UBR1−/−
UBR2−/−UBR4 RNAi cells were infected with VSVG pseudotyped HIV-1-EGFP at an MOI of 1. Viral cDNA products were quantified by qPCR at
indicated times. (A) First jump products. The data are expressed as relative to the control 4 hr time point. (B) 2LTR circles. The data are
expressed as relative to the control 24 hr time point. The data for the UBR1−/− UBR2−/−UBR4RNAi are the average of UBR1−/− UBR2−/−UBR4KD1
and UBR1−/− UBR2−/−UBR4KD2 cells.
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the triply deficient cells are impaired in early reverse
transcription or uncoating.
The N-end rule does not impact MLV infection
Similar to HIV-1, proteins of other retroviruses also harbor
N-terminal residues that make them susceptible to the N-
end rule. For example mature MLV integrase also bears a
type 2 destabilizing residue isoleucine making it a potential
substrate for the N-end rule pathway [26]. A comparison of
different retroviral integrase N-terminal residues revealed
that all lentiviruses examined, gammaretroviruses and
spumaretroviruses harbor destabilizing residues. However,Virus Amino acid at integrase N-term
Lentiviruses
HIV-1 Phe
HIV-2 Phe
SIV Phe
EIAV Trp
Alpharetroviruses
MAV Pro
RSV Pro
Betaretroviruses
MMTV Ser
MPMV Ser
Gammaretroviruses
MLV Iso
Deltaretroviruses
HTLV Ser
Epsilonretroviruses
WDSV Val
Spumaretroviruses
HFV Cys
Figure 4 Only some retroviral integrases bear a N-terminal type-2 de
amino acid at the N-terminus of mature integrase for various retroviruses. R
sequence characterization of the cleavage site or the integrase protein fromthis is not universal to retroviruses, since alpha, beta,
delta and epsilon retroviruses harbor a stabilizing resi-
due (Figure 4). To test whether MLV infection is affected
by the impairment of the N-end rule pathway, we infected
our N-recognin deficient MEFs using a MLV based EGFP
vector pseudotyped with VSVG. In contrast to HIV-1,
MLV infectivity was only slightly decreased in UBR1−/−
UBR2−/− UBR4KD cells compared to the other cells
tested (Figure 5). Notably the slight decrease was also
present in the control UBR1 −/−, UBR2 −/−, Luciferase
RNAi cell line. This leads us to conclude that the impact
of the N-end rule on MLV infection is minimal. This
also allows us to conclude that the decrease observedinus N-end rule designation References
Primary Destabilizing 21, 22, 44
Primary Destabilizing 19
Primary Destabilizing 43
Primary Destabilizing 45
Stabilizing 19
Stabilizing 47
Stabilizing 19
Stabilizing 50
Primary Destabilizing 21
Stabilizing 49
Stabilizing 48
Secondary Destabilizing 46
stabilizing residue. A comparison of the identity and nature of the
epresentatives of the family of retroviruses were chosen based on
the literature [22,26-35].
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Figure 5 MLV infectivity is not affected in N-recognin deficient cell. WT and N-recognin deficient MEFs were infected with VSVG
pseudotyped MLV-EGFP at an increasing MOI of 0.25, 0.5 and 2.5. The percent of GFP positive cells were determined by fluorescence cytometry
3 days post infection.
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http://www.virologyj.com/content/10/1/233for HIV-1 on the triply deficient cells is not due to an entry
defect since the MLV and HIV vectors are pseudotyped
with VSVG and hence utilize the same mode of entry.
The N-terminal residue impacts intravirion stability
of integrase
The observed differential effect of N-recognin deficiency
on HIV-1 and MLV prompted us to question the previous
suggestions that HIV-1 integrase stability may be con-
trolled by the N-end rule pathway during viral life cycle.
To better assess the possible involvement of the N-end
rule pathway in controlling integrase stability during
retroviral infection, we generated N-terminal integrase
point mutants of HIV-1 and MLV with an N-terminal
stabilizing or destabilizing residue within the context of
the GagPol protein (see Tables 2 and 3). For both viruses
we chose methionine as the stabilizing residue since
HIV-1 mutants with this residue at the N-terminus have
previously been shown to produce virions [21]. Both
HIV-1 and MLV mature integrases bear a type 2 desta-
bilizing residue at their N-terminus [26]. Hence, we also
substituted the WT destabilizing residues of both viruses
with another, structurally similar type 2 destabilizing residueTable 2 N-terminal integrase mutants of HIV-1
Cleavage site (RH/INT) N-end rule designation Amino acid at P1’
RKVL/FLD (WT) Destabilizing Phenylalanine
RKVL/MLD Stabilizing Methionine
RKVL/WLD Destabilizing Tryptophanas an additional control. For HIV-1 we replaced phenyl-
alanine at the N-terminus of integrase with another aro-
matic amino acid, tryptophan (Table 2). For the integrase
of MLV, we replaced isoleucine with another branched
chain amino acid, leucine (Table 3). In order to evaluate
correct packaging and maturation of viral proteins in our
integrase mutants, we analyzed viral pellets by immuno-
blotting. As shown in Figure 6A, HIV-1 integrase mutants
successfully produced viral particles as evidenced by the
presence of the mature capsid protein (p24) in the con-
centrated viral pellets. However, the amount of integrase
was decreased in these mutants compared to WT virus.
Levels of reverse transcriptase subunits found in the viral
particles paralleled the decreased levels of integrase. In
contrast levels of integrase were not significantly altered
for the MLV integrase mutants (Figure 6B).
HIV-1 Integrase mutants package equivalent amounts
of GagPol
The observed reduction in the amount of integrase and
reverse transcriptase suggested a possible defect in the
processing of viral Gag Pol polyprotein. To better assess
the effect of N-terminal residue integrase mutants ofTable 3 N-terminal integrase mutants of MLV
Cleavage site (RH/INT) N-end rule designation Amino acid at P1’
STLL/IEN (WT) Destabilizing Isoleucine
STLL/MEN Stabilizing Methionine
STLL/LEN Destabilizing Leucine
WT Met Trp
MLV 
(ctrl) HIV 
(ctrl)
Leu WTMet
p24
Integrase
RT
Integrase
p30
A B
Figure 6 Intravirion integrase levels are decreased in HIV-1 integrase N-terminal mutants. HIV-1 or MLV virions were produced in 293T
cells using helper plasmids with either WT or engineered mutations for the N-terminus of mature integrase. Virions particles were concentrated
and capsid equivalent (p24 for HIV-1 and p30 for MLV) extracts were analyzed by immunoblot analysis. A) HIV-1 vector particle extracts probed
with p24, integrase or RT antibodies. The MLV (ctrl) particle extract serves as a negative control. B) MLV vector particle extracts probed with p30
or MLV integrase antibodies. The HIV (ctrl) extract serves as a negative control.
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http://www.virologyj.com/content/10/1/233HIV-1 on viral proteolytic processing, we analyzed the
intravirion accumulation of Gag, Gag Pol and other pro-
teolytic processing intermediates. We generated WT and
integrase mutant virions in the presence of increasing
amounts of an HIV-1 protease inhibitor, ritonavir. On
probing with a p24 antibody WT and mutant virions
showed similar patterns of processing intermediates
indicated by the decrease in the level of p24 and p32
followed by an increase in the level of higher molecular150
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Figure 7 Intravirion processing of Gag and Gag-Pol polyproteins in H
particles were produced in the presence of varying concentrations of the H
and Gag Pol polypeptides were analyzed by immunoblot analysis. WT, met
mutants were probed with antibodies to integrase (top) or p24 (bottom).weight products such as p55 Gag and p160 Gag Pol as
the concentration of ritonavir increased (Figure 7). Gag
processing is unaffected by the integrase N-terminal mu-
tations as both WT and mutant virions showed identical
patterns of cleavage intermediates (Figure 7, bottom).
Virions produced at the highest concentrations of ritonavir
(10 μM) contained similar amounts of Gag and Gag Pol
suggesting similar levels of packaging of these polyproteins
into virions. Probing with an integrase antibody revealedIntegrase
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http://www.virologyj.com/content/10/1/233similar processing intermediates p121 or p114 between
wild-type and mutant virions (Figure 7, top). The larger
proteolytic processing intermediates observed are consist-
ent with previous studies and predictions based on the
cleavage sites in the Gag and Gag Pol proteins [27,36].
We have observed an intermediate band between 40
and 50 kDa that appears in the presence of suboptimal
ritonavir concentrations. Although this fragment may
indicate an alternative cleavage site induced by the mu-
tation at the N terminal residue of Integrase, we have
not observed the same fragment in separate virus batches
produced in the absence of ritonavir (Additional file 2:
Figure S2). Indeed separate experiments with ritonavir
have revealed a similar fragment in suboptimal concen-
trations of ritonavir in both mutants and the WT virus
(Additional file 2: Figure S2). Additionally we observe
only slight differences in both infectivity and the amount
of reverse transcriptase products in different batches of
virus preparations (Figure 8A and C). Hence this fragment
is a bona fide cleavage intermediate that is not induced by
the mutations at the N-terminus of integrase. Collectively
these results indicate that protease cleavage site preference0
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Figure 8 Effect of N-terminal Integrase mutations on HIV-1 and MLV vir
equilibrated to p24 (HIV-1) or p30 (MLV) amounts were incubated with Jurkat
infection. MOI for WT was measured as indicated in the Methods section and
used for integrase mutants C) HIV-1 vectors at an MOI of 1 were incubated w
qPCR at indicated times. The data are expressed as relative to the control (wilis not affected by the mutations at the integrase N-
terminal residue. However in the presence of a fully ac-
tive protease the absolute levels of integrase decreased
(compare total signal between WT and mutant virions
at 0 μM ritonavir) suggesting that the loss of integrase
in the mutants requires HIV-1 protease activity.The N-terminal mutants of HIV-1 but not MLV
impact infection
Next, we tested the infectivity of these mutants in hu-
man cells. As shown in Figure 8A, infectivity was 10–20
folds lower for both HIV-1 integrase mutants compared
to wild-type virus. In contrast, MLV integrase mutants
exhibited slight decreases in infectivity compared to WT
virus in Jurkat cells (Figure 8B). Notably the levels of
integrase in the met or trp mutants vary (Figures 6, 7
and Additional file 2: Figure S2) but the levels of infec-
tion are equally refractory indicating that the defect is
due to a function of the N-terminal amino acid in the
RT/uncoating process rather than a defect in proteolytic
processing.2.5
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http://www.virologyj.com/content/10/1/233Although the main catalytic function of retroviral
integrase is to integrate viral double stranded DNA
into the host cell chromosome, numerous studies have
demonstrated the impact of mutations in the integrase
protein on various viral processes including uncoating
[37], nuclear import [38,39] and reverse transcription
[38,40-44]. In order to determine which step(s) of the
viral life cycle is affected by the HIV-1 integrase N-
terminal mutants, we measured relative viral DNA ac-
cumulation at different time points following infection
of the Jurkat cells using quantitative PCR analysis. As
shown in Figure 8C, both methionine and tryptophan
mutants of HIV-1 integrase showed substantially
lower first jump products compared to WT integrase.
Approximately 10–20 fold decrease was observed at 6
and 18 hours post infection. These results indicate
that the severe inhibition of HIV-1 infection caused by
the substitution of the N-terminal residue of viral
integrase is the result of a block at the reverse transcrip-
tion or uncoating step of the viral life cycle.0
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Figure 9 HIV-1 Integrase N-terminal mutants behave similarly in N-re
vectors were used to infect N-recognin deficient cells. The infectivity was m
relative to infection of the UBR1−/− UBR2−/− cell line.N-end rule pathway doesn’t target integrase during
retroviral life cycle
The finding that both stabilizing and destabilizing N-
terminal mutants of HIV-1 exhibited similarly decreased
infectivity levels supports our hypothesis that integrase is
not affected by the N-end rule pathway during viral life
cycle. We further tested this hypothesis in experiments
using viral mutants and cellular mutants in the N-end
rule. If integrase is affected by the N-end rule pathway,
the stabilizing N-terminal mutant (methionine) would
show similar infectivity on different N-recognin deficient
MEFs, while our destabilizing mutant (Tryptophan) would
behave like the WTvirus. In contrast to these expectations
our mutants showed the same pattern in their infectivity
of N-recognin deficient MEFs (Figure 9). All HIV-1 mu-
tants showed a 5–6 fold decrease in infectivity when all
three ubiquitin ligases are depleted compared to UBR1−/−
UBR2−/− cells. In contrast WT MLV and MLV integrase
mutants were only slightly decreased and this could be at-
tributed to the overexpression of shRNA since the control0
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http://www.virologyj.com/content/10/1/233luciferase knockdown also resulted in a decrease in infec-
tion (Figure 10).
Discussion
In this study we set out to investigate the role of the
N-end rule ubiquitin protease degradation pathway in
the retroviral life cycle. This pathway has the poten-
tial to act on viral proteins that are generated from
polyproteins by protease cleavage. The resultant N-
terminal amino acid can vary from the canonical me-
thionine of most proteins and the mature protein can
be subject to rapid degradation according to the N-end
rule [12]. In looking at HIV-1 by sequence comparison we
identified 7 mature proteins that are predicted to have a
short half-life according to the N-end rule (Table 1). Com-
paring 1850 sequences at the Los Alamos HIV Sequence
Database that includes all subtypes of HIV-1 and SIVcpz
showed an absolute conservation for the N-terminal resi-
due of the mature proteolytically cleaved form of 4 pro-
teins (p1, TFP, RNaseH and Integrase). Figure 1
illustrates this for the integrase sequence. Since N ter-
minal amino acid residue for these 4 proteins is under0
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Figure 10 MLV Integrase N-terminal mutants behave similarly in N-re
vectors were used to infect N-recognin deficient cells. The infectivity was m
relative to infection of the UBR1−/− UBR2−/− cell line.selective pressure to be conserved, we reasoned the resi-
due at this site might interact with cellular pathways /
proteins.
We initially used cell lines that were genetically
inactivated for the E3 ligases involved in the N-end
rule recognition N-recognins UBR1, UBR2 and UBR4
[18]. From the reported overlap and redundancy in
function we utilized cell lines that were multiply
inactivated for combinations of the N-recognins. We
show that while HIV-1 infection is impacted when all
three recognins are inactivated, MLV infection is only
marginally affected. This result implied that an N-end
rule target protein in the host cell is involved in
HIV-1 infection and its stabilization results in a re-
duction of infection. We also conclude that this pro-
tein interacts with HIV-1 but not with MLV and the
interaction is not conserved between retroviruses. An
alternative hypothesis was that the N-end rule path-
way interacts with a protein or proteins from HIV-1
but not MLV. Regardless of the mode of action we de-
termined that the block to infection is at reverse tran-
scription or uncoating.0
20
40
60
80
100
120
In
fe
ct
iv
it
y
(%
 o
f 
U
B
R
1-
/-
U
B
R
2-
/-
) 
Leu
cognin deficient cells. WT and integrase mutant (Leu and Met) MLV
easured by flow cytometry 3 days post infection and is expressed
Boso et al. Virology Journal 2013, 10:233 Page 11 of 14
http://www.virologyj.com/content/10/1/233In order to determine the potential viral target of the
N-end rule pathway we decided to examine the role of
HIV-1 proteins. We initially focused this study on the
integrase molecule because it has previously been shown
to be a target for the N-end rule [18,20,21] and it has
been a focus for the development of small molecule
inhibitors in recent years. Previous data had demon-
strated that ectopically expressed integrase with a de-
stabilizing residue was unstable and this instability can
be rescued in N-recognin mutants [18]. These studies
were extended by using ubiquitin integrase fusions that re-
placed the N – terminus of integrase with various amino
acids and these experiments validated the action of the
N-end rule again on ectopically expressed forms of integrase
[18]. However these studies did not determine if the
integrase was a target for the N-end rule during infection.
Hence the question remained whether the N-terminus of
integrase was open to interaction with N-recognins in
the context of the reverse transcription complex or the
pre-integration complex. These are large molecular as-
semblies in which integrase plays a role. One report did
study the N-terminal phenylalanine of integrase in the
context of viral infection by mutating the phenylalanine
to the stabilizing methionine residue [21]. In this study
the authors also mutated the C- terminus of reverse
transcriptase to compensate for any defect in proteolytic
processing due to the N-terminal substitution. These
authors reported that infection was greatly reduced in
the methionine (and compensation) mutant and they
speculate that this may be due to the stability of
integrase by extrapolating the data from the previous re-
ports [18,20]. In this study we included an additional
control by mutating the destabilizing WT residue, phenyl-
alanine to another destabilizing and structurally conservative
aromatic amino acid tryptophan. We found no absolute
defect in proteolytic processing by the single amino acid
mutation as reported previously [21]. We found that infec-
tion was decreased for both mutations compared to the
WT virus (Figure 8A). This result suggests that the severe
inhibition of infectivity caused by the amino acid substitu-
tion at the N-terminal residue of HIV-1 integrase is not
related to the N-end rule pathway. It further confirms that
the identity of the N-terminal amino acid of integrase for
HIV-1 is vital to its function and explains the tremendous
selection pressure that results in this phenylalanine resi-
due being absolutely conserved. This function is unique
for HIV-1 since mutating the N-terminal residues of MLV
had little impact on infection of MLV.
We further observed that mutating the N-terminal
amino acid in integrase resulted in intravirion instability
of the integrase molecule (Figure 6). Intravirion instability
of the members of the Pol polyprotein has been observed
in previous studies [45,46]. We confirm that this instabil-
ity is in part due to the action of HIV-1 protease since thestability of mutant proteins is restored by inhibiting the
protease (Figure 7). This result suggests that HIV-1 prote-
ase may degrade the mutant proteins in the virion or that
it initiates a cleavage that is acted upon by other proteases
packaged virion particles.
Since the N-terminal mutant integrase in the virion
still enabled low levels of infectivity, we tested the mutant
HIV-1 virions in N-recognin deficient cells. We found that
all mutants had a decreased titer on the triply deficient
cells compared to the UBR1 −/− UBR2 −/− cells (Figure 9).
This reduction was not observed for MLV and mutants at
the N-terminus of its integrase (Figure 10). These re-
sults support our conclusion that HIV-1 integrase in the
context of infection is not a target for the N-end rule
pathway.
Our results also point to the importance of the first
amino acid phenylalanine of HIV-1 integrase in its func-
tion. This residue is often changed using recombinant
DNA techniques used to manipulate the integrase cod-
ing sequence. Typically this involves adding a methio-
nine start codon to the protein to enable expression of
the integrase molecule [47]. Moreover in structural studies
residual epitope tags are left as N-terminal extensions
after protein purification [48]. Hence future studies should
aim to retain the N-terminal phenylalanine especially if
integrase is studied in a complex with other proteins.
Since in vitro assays for integrase function are efficient
with recombinant N-terminal methionine bearing mole-
cules, and we have eliminated interaction of the N-
terminus with the N-end rule machinery, we speculate
that an N-terminal interaction with cellular or viral
components involving the phenylalanine is crucial for
the early pre-integration phase of HIV-1 infection. Con-
sidering the absolute conservation of this residue, this
interaction may be a potent target for small molecules
to disrupt the viral life cycle.
Conclusions
We conclude that HIV-1 integrase is not a direct target
for the N-end rule pathway mediated degradation dur-
ing infection. Further the nature of the N-terminal resi-
due of integrase is vital for the infectivity of HIV-1, but
not MLV.
Materials and methods
Reagents, plasmids and mutagenesis
WT, UBR4 RNAi, UBR1−/−, UBR2−/− and UBR1−/−
UBR2−/−, UBR1−/− UBR2−/−UBR4RNAi and UBR1−/−
UBR2−/−LuciRNAi cell lines were previously established
[18,49,50]. 293T and Jurkat cells were obtained from
American Type Culture Collection (ATCC). The follow-
ing reagents were obtained through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID,
NIH; p24 Monoclonal Antibody (183-H12-5C) from
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Integrase Antiserum (aa 23–34)from Dr. Duane P.
Grandgenett, HIV-1 RT Monoclonal Antibody (MAb21)
from Dr. Stephen Hughes, Ritonavir. The anti-p30 to
MLV was collected from a hybridoma cell line obtained
from the ATCC (CRL-1912). Secondary p24 antibody for
ELISA was collected from a hybridoma cell line obtained
from ATCC (HB-9725). Antibody isolation from the hy-
bridoma cell lines were performed using standard proto-
cols [51]. MLV integrase rabbit polyclonal antibody was a
kind gift from Dr. Monica Roth.
Goat-anti-mouse-horseradish peroxidase and goat-anti-
rabbit-horseradish peroxidase (HRP) secondary antibodies
and West Femto enhanced chemiluminescent (ECL)
HRP substrate were obtained from Thermo Scientific
(Rockford, IL). Secondary antibody for ELISA; goat-anti-
mouse-HRP IgG2A was obtained from Southern Biotech
(Birmingham, AL).
Following plasmids were used in this study: CSII-EGFP;
an HIV-1 based vector encoding for GFP driven by EF-1a
promoter [52]. CSII-DSRed; an HIV-1 based vector en-
coding for Ds-Red. CSII-CMVGFP; an HIV-1 based vector
encoding for GFP driven by CMV promoter. ΔNRF [53];
encodes for gag, pol, rev, tat and vpu of HIV-1. pMDG
[54]; encodes for vesicular stomatitis virus glycoprotein.
pCLMFG-GFP [55]; and MLV based vector encoding for
GFP, pCMVgp [55]; encodes for gag and pol of MLV.
Mutations at the N terminal of HIV-1 and MLV integrase
were introduced to ΔNRF and pCMVgp respectively using
QuickChange site-directed mutagenesis kit (Stratagene,
La Jolla, CA).Virus production, infections and culture conditions
HIV-1 and MLV vectors were generated by transient
transfection of three plasmids into 293T cells as described
previously [54,55]. For HIV-1 vectors 15 μg of CSII EGFP,
10 μg of ΔNRF and 5 μg of pMDG were transfected using
the method of Chen and Okoyama [56]. 72 hours after
transfection virus was collected and filtered through a
0.45 μM membrane. Following normalization via p24
ELISA, filtered virus was concentrated by ultracentrifu-
gation (100,000 × g, 2 hours at 4°C). Viral pellet was
resuspended in Phosphate buffer saline (PBS) and ali-
quots were stored at −80°C. Viral titers were determined
by infecting 1 × 105 Jurkat cells with 10 fold dilutions of
the viral preparation. 72 hours after the infection EGFP
expression was quantified by flow cytometryon a Becton-
Dickinson FACScalibur. Same procedure was followed for
production of MLV vectors using following plasmids; 15 μg
of pCLMFG-GFP, 10 μg of pCMVgp and 5 μg of pMDG.
MEFs and 293T cells were maintained in Dulbecco’s
Modified Eagle Medium (Cellgro) supplemented with 10%
Fetal Bovine Serum, FBS (Gemini Bioproducts). Jurkat cellswere maintained in Iscove’s Modified Dulbecco’s Medium
(ATCC) supplemented with 20% FBS.
Reverse transcription products qPCR assay
1 × 105 cells were plated into 6 well dishes and infected at
an MOI of 1. To control for DNA contamination, the
virus was treated with 50 units/mL Benzonase (Sigma) for
1 hour at 37°C before it was added to the cells. Infections
were synchronized by incubating the cells 30 minutes at
4°C before and after the addition of the virus. Controls
consisted of uninfected cells or cells infected with heat
inactivated virus for 36 hours. Cells were harvested and
washed with PBS at different time points. Cell lysates were
prepared by resuspending the cell pellet in lysis buffer
(Tris pH 8.0, 25 mM EDTA pH 8.0, 100 mMNaCl, 1%
Triton X-100, and 2 mg/ml proteinase K) and incubating
at 55°C overnight. Samples were then incubated at 95°C
for 15 minutes to inactivate proteinase K. Lysates were
used directly for qPCR analysis. Following primers were
used for qPCR [57]: U31 and U32 for first jump products,
MHC535 and MHC536 for 2LTR circles: 5' β-actin-ATC
ATG TTT GAG ACC TTC AA, 3' β-actin-AGA TGG
GCA CAG TGT GGG T, U31 - GGA TCT ACC ACA
CAC AAG GC, U32 – GGG TGT AAC AAG CTG GTG
TTC, MH535 – AAC TAG GGA ACC CAC TGC TTA
AG, MH536 – TCC ACA GAT CAA GGA TAT CTT
GTC. QPCR reactions using SYBR green were performed
using Eppendorf real plex master cycler ep and BioRad
SYBR SuperMix following the manufacturers protocol.
Cycling conditions used were 95°C for 2 min, followed by
40 cycles of 95°C 30 s, 58°C 30 s, and 72°C 30 s, and a final
extension of 5 minutes at 72°C for all PCR products. Cycle
threshold value was used to normalize the DNA amounts
to the first time point of the control sample. The melt
curve as well as analysis of the PCR products by agarose
gel electrophoresis confirmed the presence of one product
at the expected size (data not shown). DNA input was
controlled by qPCR amplification of a fragment of the
β-actin gene.
Enzyme-linked immunosorbent assay (ELISA)
A 96 well plate (NuncMaxisorp, Fisher Scientific) was
coated with a primary p24 antibody (183-H12-5C) in
coating buffer (100 mM Sodium Bicarbonate, pH 8.5) and
incubated overnight. Wells were then washed 3 times with
Phosphate Buffer Saline-Tween (PBS-T) and blocked for
1 hour using 5% milk in PBS-T at room temperature.
Following a 3xwash with PBS-T, viral samples were added
to the wells at different concentrations in Sodium Chloride-
Tris-EDTA (STE) buffer-empigen (0.1 M NaCl, 10 mM
Tris–HCl (pH 8.0), 1 mM EDTA (pH 8.0), 0.1% empigen)
in triplicates and incubated at 37°C for 1 hour. Wells were
then washed 3× with PBS-T and secondary p24 antibody
(31-90-25) was added to each well and incubated at room
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goat-anti-mouse IgG2A-HRP was added to the wells
and incubated for 30 minutes at room temperature.
Wells were then washed 3× with PBS-T and 3,3′,5,5′-
Tetramethylbenzidine, TMB (Sigma) was added to the
wells. Following a 10 minute incubation at room temper-
ature, the reaction was stopped with 2N H2SO4. Absorb-
ance was determined at 450 nm using a microplate reader
(BioTEK, SynergyMX).
Immunoblotting for viral proteins
Filtered virus containing supernatants were concentrated
as described above. Following normalization for p24 via
ELISA, viral pellets were solubilized in loading buffer
(0.25M Tris–HCl, pH 6.8, 15% SDS, 50% glycerol, 25%
β-mercaptoethanol, 0.01% bromophenol blue) and proteins
were separated by SDS-PAGE on a 12% polyacrylamide
gel and subjected to immunoblotting using the antibodies
indicated.
Analysis of intravirionproteolytic processing of
HIV-1 polyproteins
293T cells (1 × 106) were transfected using the method of
Chen and Okoyama [56] with 15 μg of CSII EGFP, 5 μg of
pMDG, and 10 μg of ΔNRF which contains different mu-
tations corresponding to the relevant integrase N-terminal
mutant. 8 hours later transfection medium was replaced
with culture medium containing different concentrations
of the HIV-1 protease inhibitor, ritonavir. 48 hours later
virus was collected, filtered and centrifuged at 100,000 × g
for 2 hours at 4°C. Purified virions were quantified by p24
ELISA and protein composition of the virions was assessed
by immunoblotting as described above.
Additional files
Additional file 1: Figure S1. Decrease in infectivity in triply deficient
cells is not due to a defect in reporter gene expression. UBR1−/− UBR2−/−,
UBR1−/− UBR2−/−UBR4KD and UBR1−/− UBR2−/−Luci RNAi cells were
infected with VSVG pseudotyped HIV-1 based vectors encoding either
DS-Red or GFP at an MOI of 0.5. The percent of GFP or DS-Red positive
cells were determined by fluorescence cytometry 3 days post infection.
Additional file 2: Figure S2. Intravirion processing of Gag and Gag-Pol
polyproteins in HIV-1 integrase N-terminal mutants. WT and mutant HIV-1
virion particles were produced in the presence of varying concentrations
of the HIV-1 protease inhibitor ritonavir and the cleavage pattern of the
Gag and GagPol polypeptides were analyzed by immunoblot analysis.
WT, methionine substituted (Met) and tryptophan substituted (Trp)
integrase mutants were probed with antibodies to integrase.
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